Brenner D E, Anthony L B, Halter S, Harris N L, Collins J C, Hande K R
Cancer Res. 1987 Jun 15;47(12):3259-65.
A model of hepatic dysfunction in vivo has been developed in rabbits to determine the effects of sublethal hepatocellular necrosis upon doxorubicin pharmacology. Eight New Zealand white rabbits were given 3 mg/kg doxorubicin i.v. Plasma doxorubicin and metabolite pharmacokinetics were determined and toxicity assessed by nadir complete blood counts. Hepatic function was assessed by the pulmonary excretion rate of 14CO2 from [14C]aminopyrine. Hepatocellular necrosis was produced by i.v. injection of 1.35 mg/kg of a 2% allyl alcohol solution. Doxorubicin administration and pharmacokinetics were repeated. Doxorubicin enhances the hepatotoxicity of allyl alcohol. Hepatocellular necrosis does not alter the plasma pharmacokinetics of doxorubicin but does increase the plasma exposure of doxorubicinol. Doxorubicin-induced myelosuppression is enhanced by allyl alcohol pretreatment. These data suggest that in circumstances of reduced hepatocellular volume or acute hepatocellular necrosis, a key plasma marker of doxorubicin-induced acute toxicity may be doxorubicinol.
已在兔子体内建立了肝功能障碍模型,以确定亚致死性肝细胞坏死对阿霉素药理学的影响。给八只新西兰白兔静脉注射3mg/kg阿霉素。测定血浆阿霉素和代谢物的药代动力学,并通过最低点全血细胞计数评估毒性。通过[14C]氨基比林的14CO2肺排泄率评估肝功能。通过静脉注射1.35mg/kg的2%烯丙醇溶液产生肝细胞坏死。重复给予阿霉素并测定其药代动力学。阿霉素会增强烯丙醇的肝毒性。肝细胞坏死不会改变阿霉素的血浆药代动力学,但会增加阿霉素醇的血浆暴露量。烯丙醇预处理会增强阿霉素诱导的骨髓抑制。这些数据表明,在肝细胞体积减少或急性肝细胞坏死的情况下,阿霉素诱导的急性毒性的关键血浆标志物可能是阿霉素醇。